Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01 2022 - 3:01PM
Business Wire
Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the
development of medicines that control the expression of genes,
today announced the grant of restricted stock unit (RSU) awards for
an aggregate of 48,400 shares of Syros common stock to two newly
hired employees in connection with their commencement of employment
with Syros. These RSUs were granted as material inducements to
employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs were granted on June 30, 2022, vest in equal annual
installments over a period of four years, subject to the employee’s
continued service with Syros, and are subject to the terms and
conditions of a restricted stock unit agreement covering the award
and Syros’ 2022 Inducement Stock Incentive Plan.
About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the
expression of genes. Based on its unique ability to elucidate
regulatory regions of the genome, Syros aims to develop medicines
that provide a profound benefit for patients with diseases that
have eluded other genomics-based approaches. Syros is advancing a
robust clinical-stage pipeline, including: tamibarotene, a
first-in-class oral selective RARα agonist in RARA-positive
patients with higher-risk myelodysplastic syndrome and acute
myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in
patients with acute promyelocytic leukemia; and SY-5609, a highly
selective and potent oral CDK7 inhibitor in patients with select
solid tumors. Syros also has multiple preclinical and discovery
programs in oncology and monogenic diseases. For more information,
visit www.syros.com and follow us on Twitter (@SyrosPharma) and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220701005063/en/
Media Contact Courtney Solberg Syros Pharmaceuticals
917-698-9253 csolberg@syros.com
Investor Contact Hannah Deresiewicz Stern Investor
Relations, Inc. 212-362-1200 hannah.deresiewicz@sternir.com
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Apr 2024 to May 2024
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From May 2023 to May 2024